The U.S. digital therapeutics market size was valued at $1.16 billion in 2019 and is expected to reach $5.08 billion by 2027 with a CAGR of 19.2% during the forecast period. Digital therapeutics provides evidence-based therapeutic interventions to patients. It is driven by software programs and devices to prevent, manage, or treat a medical condition. Digital therapeutics software application can be used independently or in combination with devices, medications, or any other therapies to provide patient care and health outcomes. These products incorporate advanced technology, best practices regarding the design, usability, clinical validation, and data security. These products are reviewed and approved by regulatory bodies before use. Furthermore, digital therapeutics empower patients, healthcare providers, and payers with intelligent and accessible tools for addressing a wide range of conditions through high quality, safe, and effective data-driven interventions.
Increase in adoption of smartphones and tablets coupled with healthcare apps, growth in need to control healthcare cost, and rise in incidence of chronic diseases drive the growth of the U.S. digital therapeutics market. However, lack of awareness regarding digital therapeutics and patient data privacy concerns restrain the market growth. The impact of the driving factors is expected to surpass that of the restraints. Hence, the market is projected to grow at a CAGR of 19.2% from 2020 to 2027. On the contrary, favorable laws and regulations for digital health technology and increase in investments in digital therapeutics are anticipated to offer significant growth opportunities for the market players in the future.
The U.S. digital therapeutics market is segmented into application, product type, sales channel, and region. By application, it is divided into diabetes, obesity, cardio vascular diseases (CVD), central nervous system (CNS) disease, respiratory diseases, smoking cessation, gastrointestinal disorders, and others. By product, it is classified into software and devices. Further, on the basis of sales channel, it is bifurcated into business-to-business (B2B) and business-to-consumers (B2C). Furthermore, business-to-business (B2B) is categorized into employer & payer, healthcare providers, and others. By business-to-consumers, it is classified into patients and caregivers.
Key Benefits for Stakeholders
Key Market Segments
By Application
By Product
By Sales Channel
Key Market Players
The other players in the value chain include (profiles not included in the report):
Increase in adoption of smartphones and tablets coupled with healthcare apps, growth in need to control healthcare cost, and rise in incidence of chronic diseases drive the growth of the U.S. digital therapeutics market. However, lack of awareness regarding digital therapeutics and patient data privacy concerns restrain the market growth. The impact of the driving factors is expected to surpass that of the restraints. Hence, the market is projected to grow at a CAGR of 19.2% from 2020 to 2027. On the contrary, favorable laws and regulations for digital health technology and increase in investments in digital therapeutics are anticipated to offer significant growth opportunities for the market players in the future.
The U.S. digital therapeutics market is segmented into application, product type, sales channel, and region. By application, it is divided into diabetes, obesity, cardio vascular diseases (CVD), central nervous system (CNS) disease, respiratory diseases, smoking cessation, gastrointestinal disorders, and others. By product, it is classified into software and devices. Further, on the basis of sales channel, it is bifurcated into business-to-business (B2B) and business-to-consumers (B2C). Furthermore, business-to-business (B2B) is categorized into employer & payer, healthcare providers, and others. By business-to-consumers, it is classified into patients and caregivers.
Key Benefits for Stakeholders
- This report provides a detailed quantitative analysis of the current U.S. digital therapeutics market trends and future estimations from 2020 to 2027, which assists to identify the prevailing market opportunities.
- An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate country-specific plans.
- A comprehensive analysis of the factors that drive and restrain the growth of the U.S. digital therapeutics market is provided.
- An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
Key Market Segments
By Application
- Diabetes
- Obesity
- Cardiovascular Disease (CVD)
- Central Nervous System (CNS) Disease
- Respiratory Disease
- Smoking Cessation
- Gastrointestinal Disorder (GID)
- Others
By Product
- Software
- Device
By Sales Channel
- Business-to-Business (B2B)
- Employer and Payer
- Healthcare Provider
- Others
- Business-to-Consumer (B2C)
- Patient
- Caregiver
Key Market Players
- 2MORROW, Inc.
- Fitbit, Inc. (Twine Health, Inc.)
- Livongo Health, Inc.
- Medtronic Plc.
- Omada Health, Inc.
- Pear Therapeutics, Inc.
- Proteus Digital Health, Inc.
- Resmed, Inc. (Propeller Health)
- Voluntis, Inc.
- Welldoc, Inc.
The other players in the value chain include (profiles not included in the report):
- Canary Health Inc.
- Mango Health Inc.
- Noom, Inc.
- Dthera Sciences
Table of Contents
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Overview
Chapter 4: Digital Therapeutics Market, by Application
Chapter 5: Digital Therapeutics Market, by Product
Chapter 6: Digital Therapeutics Market, by Sales Channel
Chapter 7: Company Profiles
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
